Tokyo, December 14, 2022 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: TokyoGeneral Manager: Haruo Naitom“Isai”) Today Isai and University of Washington School of Medicine at St. Louis They have entered into a comprehensive research collaboration agreement aimed at developing new treatments for neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).

University of Washington It is a world leader in research on prevention, diagnosis, biomarkers and treatment of neurodegenerative diseases. The two organizations collaborated in AD research. A phase II/III tau NexGen study of an anti-MTBR (microtubule binding) assay is exploring the safety, tolerability, biomarkers, and cognitive efficacy of the Advanced Indigenous Alzheimer’s Network Trials Unit (DIAN-TU) led by the university’s School of Medicine. region) tau antibody E2814 Treatment of predominantly hereditary Alzheimer’s disease (DIAD). In this study, the anti-amyloid beta (Aβ) protofibril antibody lecanemab (generic name, development code: BAN2401) was chosen as the background anti-amyloid agent.

The collaboration combines strategically. University of Washington The scientists’ extensive experience in drug discovery and development combined with expertise in basic and clinical research into neurodegenerative diseases such as dementia. Using human biology, the goal is to generate multiple novel therapeutic candidates and discover and identify biomarkers over the next five years. Esai will have option rights to develop and commercialize any compounds and biomarkers that meet certain criteria in terms of research and development standards. Isai pays Isai in the event Isai elects to exercise the options. University of Washington Future sales and royalty payments for each licensed compound.

Dr. Teji Kimura, Ph.D., Academic and Industry Alliance Officer, Esai Office of Deep Human Biology (DHBL), said, “Patients with neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, struggle with unmet medical needs, which is why Neurology is a key medical area for Esai. In collaboration with the world’s leading research institutions such as University of Washington in St. LouisIsaiah is working to fulfill us Human health care Deliver new and targeted disease-modifying therapies with the ultimate goal of achieving a world free of neurodegenerative disease.

Media Inquiries:
Public Relations Department, Isaiah Co., Ltd.
+ 81 (0) 3-3817-5120

Isaiah Inc (US)
Lib Holman 201-753-1945
[email protected]

[Notes to editors]

1. About University of Washington Medical school
WashU Medicine is an international leader in academic medicine, including biomedical research, patient care and academic programs with 2,700 faculty members. The National Institutes of Health’s (NIH) research funding portfolio is the fourth largest among US medical schools, has grown 54% over the past five years, and with institutional investment, WashU Medicine is doing well. 1 billion dollars Innovation and training in basic and clinical research every year. Its faculty practice is among the top five in the nation, with more than 1,790 faculty physicians practicing at more than 60 locations, as well as BJC HealthCare’s medical staff at Barnes-Jewish and St. Louis Children’s Hospitals. Washyu Medicine has a recent history of specialization in MD/PhD training. 100 million dollars It is home to scholarship and curriculum renewal for its medical students, and top-notch training programs in every field of medicine, including physical therapy, occupational therapy, and audiology and communication sciences.

Source: Esai Inc.


ودجت أحدث المقالات للصفحة الرئيسية تظهر على الصفحة الرئيسية فقط


Leave a Reply

Your email address will not be published. Required fields are marked *